Eli Lilly agreed to buy Calytrix Bio for US$1.5 billion in its push against blood cancer
Eli Lilly agreed to acquire Calytrix Bio for US$1.5 billion, a deal the drugmaker frames within its push against blood cancer. Calytrix Bio was founded in 2025 by JP Morgan Life Sciences Private Capital and launched with funding provided by JP Morgan's venture capital division and Westlake BioPartners.
Read the full story at La República
IASummary generated by artificial intelligence from a story by La República. It may contain errors: the original source prevails.